• Subcutaneous Daratumumab — Dr. Jonathan Kaufman🔍
• Adding subcutaneous daratumumab slows advanced multiple ...🔍
• Subcutaneous Daratumumab Linked to Shorter Clinic Times for ...🔍
• POSB72 Subcutaneous Daratumumab in the Treatment of Multiple ...🔍
• Genmab Announces U.S. FDA Approval of Subcutaneous ...🔍
• Subcutaneous Daratumumab Associated With Higher Patient ...🔍
• Cost|Minimization Analysis for Subcutaneous Daratumumab in the ...🔍
• Role of Novel Subcutaneous Daratumumab in Multiple Myeloma🔍

Subcutaneous Daratumumab — Dr. Jonathan Kaufman - YouTube

The Myeloma Crowd brings information from the experts to the patients! Learn more at https://www.myelomacrowd.org/ HealthTree helps you find ...

Adding subcutaneous daratumumab slows advanced multiple ...

(HealthDay)—For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone ...

Subcutaneous Daratumumab Linked to Shorter Clinic Times for ...

Subcutaneous administration of daratumumab was linked to shorter clinic times for patients with multiple myeloma, compared with intravenous ...

POSB72 Subcutaneous Daratumumab in the Treatment of Multiple ...

This analysis assesses the budget impact of switching Italian patients currently receiving dara-IV to dara-SC.

Genmab Announces U.S. FDA Approval of Subcutaneous ...

Company Announcement. Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with ...

Subcutaneous Daratumumab Associated With Higher Patient ...

At a median follow-up of 7.5 months, the overall response rates were 41.1% and 37.1% for patients receiving SC and IV formulations, respectively ...

Cost-Minimization Analysis for Subcutaneous Daratumumab in the ...

By Anas Hamad, Shereen Elazzazy & 9 more. The financial effects of subcutaneous daratumumab vs intravenous daratumumab for treatment of ...

Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and ...

Optimizing Care: Discontinuing Medications Prior to Daratumumab ...

1374 Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT). Program: Oral and Poster Abstracts

Subcutaneous Daratumumab Is Not Inferior To Intravenous

Subcutaneous daratumumab is easier to administer and it causes fewer administration-related reactions. In the COLUMBIA study, the investigators ...

Subcutaneous Daratumumab Added to Pomalidomide Plus ...

KEY POINTS · The addition of SC daratumumab to pomalidomide/dexamethasone significantly prolonged progression-free survival in previously ...

Subcutaneous daratumumab with VRd improves progression-free ...

The PERSEUS trial supports the addition of daratumumab to standard VR-d and lenalidomide treatment regimens in patients with newly diagnosed multiple myeloma.

An Open-label, Multicenter, Phase 2 Study (PLEIADES)

Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES).

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

In 2020, subcutaneous (SC) daratumumab was approved for the treatment of multiple myeloma, and randomized data suggest a lower rate of IRRs compared with IV ...

An evaluation of subcutaneous daratumumab for the treatment of ...

Subcutaneous daratumumab is non-inferior to conventional intravenous daratumumab with lower risk of infusion-related reactions and decreased administration ...

A Study to Evaluate Subcutaneous Daratumumab in Combination ...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens.

Teclistamab in Combination with Subcutaneous Daratumumab and ...

Dr. Emma Searle, University of Manchester, presents the results of Cohort E of MajesTEC-2 studying the effects of Teclistamab in combination ...

A Study to Evaluate Subcutaneous Daratumumab in Combination ...

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) ...

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

The FDA approved daratumumab-hyaluronidase injection for adult patients with newly diagnosed or relapsed/refractory multiple myeloma in May 2020 ...

Subcutaneous daratumumab plus standard treatment regimens in ...

ASCT, autologous stem cell transplant; D-Rd, daratumumab subcutaneous plus lenalidomide/dexamethasone; D-VMP, daratumumab subcuta- neous plus bortezomib/ ...